HUE038234T2 - Bendamusztin és ciklopoliszacharid kompozíciók - Google Patents

Bendamusztin és ciklopoliszacharid kompozíciók

Info

Publication number
HUE038234T2
HUE038234T2 HUE14177306A HUE14177306A HUE038234T2 HU E038234 T2 HUE038234 T2 HU E038234T2 HU E14177306 A HUE14177306 A HU E14177306A HU E14177306 A HUE14177306 A HU E14177306A HU E038234 T2 HUE038234 T2 HU E038234T2
Authority
HU
Hungary
Prior art keywords
bendamustine
cyclopolysaccharide
compositions
cyclopolysaccharide compositions
bendamustine cyclopolysaccharide
Prior art date
Application number
HUE14177306A
Other languages
English (en)
Inventor
Tomasz Popek
Kishore Patel
Valery Alakhov
Grzegorz Pietrzynski
Original Assignee
Softkemo Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42631521&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE038234(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Softkemo Pharma Corp filed Critical Softkemo Pharma Corp
Publication of HUE038234T2 publication Critical patent/HUE038234T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
HUE14177306A 2009-02-25 2010-02-24 Bendamusztin és ciklopoliszacharid kompozíciók HUE038234T2 (hu)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US20854109P 2009-02-25 2009-02-25
US26994409P 2009-07-01 2009-07-01
US27136409P 2009-07-20 2009-07-20
US27929309P 2009-10-19 2009-10-19

Publications (1)

Publication Number Publication Date
HUE038234T2 true HUE038234T2 (hu) 2018-10-29

Family

ID=42631521

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE14177306A HUE038234T2 (hu) 2009-02-25 2010-02-24 Bendamusztin és ciklopoliszacharid kompozíciók

Country Status (12)

Country Link
US (2) US8436032B2 (hu)
EP (2) EP2400987B1 (hu)
JP (1) JP5654498B2 (hu)
KR (1) KR101798951B1 (hu)
CN (2) CN102421451B (hu)
AU (1) AU2010217297A1 (hu)
CA (1) CA2753641C (hu)
ES (2) ES2525257T3 (hu)
HU (1) HUE038234T2 (hu)
NO (1) NO2792369T3 (hu)
RU (2) RU2591804C2 (hu)
WO (1) WO2010097700A1 (hu)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2525257T3 (es) 2009-02-25 2014-12-19 Supratek Pharma, Inc. Composiciones de ciclopolisacárido y de bendamustina
LT2528602T (lt) 2010-01-28 2017-02-27 Eagle Pharmaceuticals, Inc. Bendamustino kompozicijos
WO2011103150A2 (en) * 2010-02-18 2011-08-25 Cephalon, Inc. Lyophilized preparations of bendamustine
US20110207764A1 (en) * 2010-02-23 2011-08-25 Valery Alakhov Cyclopolysaccharide compositions
US8383663B2 (en) 2010-07-19 2013-02-26 Supratek Pharma Inc. Bendamustine anionic-catioinic cyclopolysaccharide compositions
WO2013040286A2 (en) * 2011-09-18 2013-03-21 Euro-Celtique S.A. Pharmaceutical compositions
TWI573792B (zh) 2012-02-01 2017-03-11 歐陸斯迪公司 新穎治療劑
PT3533447T (pt) 2012-03-20 2023-05-17 Eagle Pharmaceuticals Inc Composições líquidas de bendamustina para utilização num método de tratamento de condições com resposta a bendamustina em pacientes que requerem volumes reduzidos para administração
EP2827862B1 (en) 2012-03-20 2023-12-27 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
US20230241218A1 (en) * 2012-07-10 2023-08-03 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
AU2013352141B2 (en) * 2012-11-30 2018-04-05 The Regents Of The University Of California Anticonvulsant activity of steroids
EP3043648B1 (en) * 2013-08-27 2023-09-20 Vasilios VOUDOURIS Bendamustine pharmaceutical compositions
GB201409488D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409471D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409485D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
WO2018068832A1 (en) 2016-10-11 2018-04-19 Euro-Celtique S.A. Hodgkin lymphoma therapy
GB201709405D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating ovarian cancer
GB201709402D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating t-pll
GB201709403D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating sarcoma
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
CN111201019A (zh) * 2017-10-05 2020-05-26 图贝药物有限公司 口服苯达莫司汀制剂
US11730815B2 (en) * 2018-11-26 2023-08-22 Good Health, Llc Stable liquid pharmaceutical compositions comprising bendamustine
CN111557904A (zh) * 2020-04-09 2020-08-21 比卡生物科技(广州)有限公司 苯达莫司汀组合物及其用途
JP2023529033A (ja) * 2020-04-09 2023-07-07 ビカ・バイオテック(グアンジョウ)・カンパニー・リミテッド ベンダムスチン組成物及びその用途
US20240148696A1 (en) 2022-10-25 2024-05-09 Softkemo Pharma Inc. Lyophilized bendamustine-cyclodextrin composition

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD159289A1 (de) 1981-06-01 1983-03-02 Uwe Olthoff Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen
US6407079B1 (en) 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US5068226A (en) * 1987-12-07 1991-11-26 Cyclex, Inc. Pharmaceutical preparations containing cyclodextrins and their use in iontophoretic therapies
US5602112A (en) 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
DE59607089D1 (de) * 1995-03-10 2001-07-19 Roche Diagnostics Gmbh Polypeptid-enthaltende pharmazeutische darreichungsformen in form von mikropartikeln und verfahren zu deren herstellung
DK0814778T3 (da) * 1995-03-10 2001-09-17 Roche Diagnostics Gmbh Polypeptidholdige farmaceutiske administrationsformer i form af mikropartikler og fremgangsmåde til fremstilling deraf
US6624141B1 (en) 1999-03-17 2003-09-23 The Regents Of The University Of Michigan Protamine fragment compositions and methods of use
DE10204792A1 (de) * 2002-02-06 2003-08-14 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Immuncytokine
EP1499361B1 (en) 2002-04-19 2012-08-08 Novartis AG Novel biomaterials, their preparation and use
SG176314A1 (en) * 2002-12-31 2011-12-29 Altus Pharmaceuticals Inc Human growth hormone crystals and methods for preparing them
EP1729724A4 (en) * 2003-12-31 2008-07-23 Cydex Inc INHALATION FORMULATION WITH SULFOALKYL ETHER GAMMA CYCLODEXTRIN AND CORTICOSTEROID
JP2007530654A (ja) * 2004-03-30 2007-11-01 ファイザー・プロダクツ・インク シグナル伝達阻害剤の組合せ
CN1984674A (zh) * 2004-06-07 2007-06-20 纳斯泰克制药公司 不含蛋白质或多肽类稳定剂的干扰素β鼻内制剂
NZ553024A (en) * 2004-08-03 2009-11-27 Royal College Of Surgeons Ie Phenytoin formulations, and uses thereof in wound healing
JP2008519032A (ja) * 2004-11-03 2008-06-05 キュラジェン コーポレイション Fgf−20の調合物、生成方法および使用
US20060128777A1 (en) * 2004-11-05 2006-06-15 Bendall Heather H Cancer treatments
US20060128653A1 (en) * 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of decitabine
UA94036C2 (ru) * 2005-01-14 2011-04-11 Сефалон, Инк. Фармацевтическая композиция бендамустина, предназначенная для лиофилизации
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
PT1848813E (pt) 2005-01-28 2013-07-15 Scripps Research Inst Activação de glicolípidos bacterianos de células nkt restritas ao cd1d
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
CN1846685A (zh) 2006-01-25 2006-10-18 济南帅华医药科技有限公司 含苯达莫司汀和其增效剂的缓释注射剂
US20100143481A1 (en) 2006-11-08 2010-06-10 Dinesh Shenoy Method of preparing solid dosage forms of multi-phasic pharmaceutical compositions
US8425459B2 (en) * 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
ES2373867T3 (es) 2007-03-02 2012-02-09 The University Of Wollongong Composiciones y procedimientos para el suministro de agentes anticancerosos.
CN101219113A (zh) 2008-01-28 2008-07-16 济南帅华医药科技有限公司 含苯达莫司汀的复方抗癌缓释注射剂
ES2525257T3 (es) 2009-02-25 2014-12-19 Supratek Pharma, Inc. Composiciones de ciclopolisacárido y de bendamustina
CN101606934B (zh) 2009-07-27 2011-09-28 江苏奥赛康药业有限公司 盐酸苯达莫司汀组合物

Also Published As

Publication number Publication date
KR20120015294A (ko) 2012-02-21
CA2753641A1 (en) 2010-09-02
RU2734236C2 (ru) 2020-10-13
WO2010097700A1 (en) 2010-09-02
AU2010217297A1 (en) 2011-10-20
US8436032B2 (en) 2013-05-07
JP5654498B2 (ja) 2015-01-14
NO2792369T3 (hu) 2018-09-15
ES2525257T3 (es) 2014-12-19
EP2792369B1 (en) 2018-04-18
RU2011138844A (ru) 2013-04-10
CA2753641C (en) 2014-09-16
CN102421451A (zh) 2012-04-18
KR101798951B1 (ko) 2017-11-20
RU2016124871A3 (hu) 2019-11-11
ES2675620T3 (es) 2018-07-11
CN102935080A (zh) 2013-02-20
EP2400987A4 (en) 2012-08-22
EP2400987A1 (en) 2012-01-04
US8703964B2 (en) 2014-04-22
CN102421451B (zh) 2013-11-06
US20100216858A1 (en) 2010-08-26
RU2016124871A (ru) 2018-12-04
JP2012519657A (ja) 2012-08-30
US20130190372A1 (en) 2013-07-25
EP2400987B1 (en) 2014-09-03
EP2792369A1 (en) 2014-10-22
RU2591804C2 (ru) 2016-07-20

Similar Documents

Publication Publication Date Title
HUE038234T2 (hu) Bendamusztin és ciklopoliszacharid kompozíciók
IL217949A0 (en) Pesticdal compositions
EP2488022A4 (en) Compositions
ZA201109176B (en) Homeglobin compositions
GB0906515D0 (en) Fungical compositions
GB0908129D0 (en) Composition
GB0918450D0 (en) Composition
ZA201109312B (en) Compositions
GB0909362D0 (en) Composition
PL2226355T3 (pl) Kompozycje poliolefinowe sieciowane wilgocią
GB0908642D0 (en) Composition
GB0901966D0 (en) Composition
EP2394634A4 (en) HESPERIDO-CONTAINING COMPOSITION
GB0906779D0 (en) Composition
EP2595660A4 (en) ANIONIC-CATIONIC BENDAMUSTIN CYCLOPOLYSACCHARIDE COMPOSITIONS
GB0911294D0 (en) Composition
GB0904941D0 (en) Composition
EP2485807A4 (en) SUN PROTECTION COMPOSITIONS
EP2444061A4 (en) COMPOSITION CONTAINING APIGENIN
GB0905165D0 (en) Compositions
GB0906548D0 (en) Composition
GB0904942D0 (en) Composition
GB0918590D0 (en) Composition
GB0903688D0 (en) Composition
GB0902959D0 (en) Composition